Para, M F <br/><br/>
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Jun 1999 
 - 1373-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0066-4804 
<br/><br/><label>Standard No.: </label>10.1128/AAC.43.6.1373  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acquired Immunodeficiency Syndrome--drug therapy<br/>Adult<br/>Anti-HIV Agents--therapeutic use<br/>CD4 Lymphocyte Count<br/>Delavirdine--adverse effects<br/>Dose-Response Relationship, Drug<br/>Female<br/>HIV-1--genetics<br/>Humans<br/>Male<br/>RNA, Viral--blood